Investigational drug may reduce involuntary movements

April 12, 2011

Results of the first randomized, placebo-controlled long-term clinical trial show the investigational drug safinamide may reduce dyskinesia or involuntary movements in mid-to-late stage Parkinson's disease. The findings will be presented as late-breaking research at the 63rd Annual Meeting of the American Academy of Neurology, April 9, 2011, in Honolulu.

"Our findings over a two-year treatment period suggest that taking safinamide in addition to levodopa and other dopaminergic treatments could help patients who continue to experience tremors and involuntary movement problems," said study author Ravi Anand, MD, a consultant with Newron Pharmaceuticals in Bresso, Italy. "These results are an important step forward in understanding how safinamide impacts patients with severe . Symptoms of Parkinson`s disease, motor fluctuations and dyskinesia can greatly affect a person's daily living and quality of life."

For the two-year study, 669 patients with mid-to-late stage Parkinson's disease who were already taking levodopa and other dopaminergic treatments were given 50 or 100 milligrams of safinamide per day or a placebo pill. Scientists tested participant's movement ability using the United Parkinson's disease rating scale that measures activities such as tremor, speech, behavior, mood and daily activities including swallowing, dressing and walking. A specific tool measuring severity of dyskinesia (DRS) was used in addition as primary efficacy endpoint.

At the start of the study, patients who took the 50 milligram dose of safinamide had an average score of 3.9 compared to a score of 3.4 for those taking a placebo pill. Patients who took the 100 milligram dose had an average score of 3.7.

After two years, researchers discovered in a post-hoc analysis that safinamide at 100 milligrams a day on top of taking reduced dyskinesia, or movement problems, by 24 percent in the one-third of participants who had scored a four or higher on the dyskinesia rating scale at the beginning of the study compared to those taking a placebo. There were no significant differences for people who took the 50 milligram dose.

There were no significant differences in the primary efficacy measure (movement control, i.e., dyskinesia) scores in the overall population. Side effects were comparable among the three treatment groups.

Related Stories

Recommended for you

Knowing one's place in a social hierarchy

December 7, 2016

When you start a new job, it's normal to spend the first day working out who's who in the pecking order, information that will come in handy for making useful connections in the future. In an fMRI study published December ...

Deep brain stimulation may not boost memory

December 7, 2016

Deep brain stimulation (DBS) of areas in the brain known to be involved in making memories does not improve memory performance, according to a study by Columbia University researchers published December 7 in Neuron. The study ...

Brain activity may predict risk of falls in older people

December 7, 2016

Measuring the brain activity of healthy, older adults while they walk and talk at the same time may help predict their risk of falls later, according to a study published in the December 7, 2016, online issue of Neurology.

When neurons are 'born' impacts olfactory behavior in mice

December 7, 2016

New research from North Carolina State University shows that neurons generated at different life stages in mice can impact aspects of their olfactory sense and behavior. The work could have implications for our understanding ...

Rhythm of breathing affects memory and fear

December 6, 2016

Northwestern Medicine scientists have discovered for the first time that the rhythm of breathing creates electrical activity in the human brain that enhances emotional judgments and memory recall.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.